论文部分内容阅读
Angiostatin是一种新发现的对肿瘤生长有特异抑制作用的抗血管生成因子,实验已证实其对多种肿瘤有明显的抑制作用。本文报告构建了含Angiostatin基因的真核表达载体pAG3,通过建立荷瘤小鼠模型来研究Angiostatin对人黑色素瘤B16的原位生长,植入及与化疗药物DTIC的联合作用等来探讨Angiostatin裸DNA肌肉注射的体内抗瘤效应。实验结果表明Angiostatin可明显抑制C57荷瘤小鼠的肿瘤生长;人黑色素瘤B16细胞植入前5天肌肉注射pAG3能显著阻止正常C57小鼠新肿瘤的形成;但在pAG3与DTIC联合化疗实验中,两者未表现出明显的增强效应。本实验为拓展非病毒介导的Angiostatin抗血管生成基因治疗途径奠定了基础。
Angiostatin is a newly discovered anti-angiogenic factor that specifically inhibits tumor growth. Experiments have shown that Angiostatin has a significant inhibitory effect on various tumors. This article reports the construction of an eukaryotic expression vector pAG3 containing Angiostatin gene to study the in situ growth and implantation of Angiostatin on human melanoma B16 by establishing a tumor-bearing mouse model to explore the combined effect of Angiostatin naked DNA In vivo anti-tumor effect of intramuscular injection. Experimental results show that Angiostatin can significantly inhibit tumor growth in C57-bearing mice; intramuscular injection of pAG3 5 days prior to implantation of human melanoma B16 cells significantly prevented the formation of new tumors in normal C57 mice; however, in combination with pAG3 and DTIC , Both did not show significant enhancement effect. This experiment lays a foundation for expanding the non-virus-mediated anti-angiogenic gene therapy of Angiostatin.